Archive · 30 Jan 2026
US Pushes for Drug Origin Labels
US lawmakers are trying to make it a rule for prescription drugs to show where they and their ingredients are made.
They say most medicines in the US come from other countries, like China and India, and this could be a problem if those countries stop sending drugs.
They worry about the quality and safety of these drugs and want people to know where their medicine comes from.
Experts agree that more information is good, but they also say just putting labels on drugs isn't enough.
They suggest using QR codes on medicine packages to give more details and making sure drugs made in the US are supported.
They also think the US should have a better plan in case other countries stop sending important medicine ingredients.
US lawmakers propose CLEAR LABELS Act to require country-of-origin labeling on prescription drugs.
91% of US prescriptions are for generics, with 94% using overseas active pharmaceutical ingredients (APIs).
Concerns raised about foreign drug manufacturing quality and US dependence on China and India.
Experts recommend QR codes on drug packaging and public quality data for better transparency.
Consumer preference for US/Canada-made drugs noted, but country of origin not solely indicative of quality.
- Who
- US lawmakers, Senate Special Committee on Aging, healthcare experts
- What
- Push for country-of-origin labeling on prescription drugs
- When
- During a recent hearing, with record open until next week
- Where
- United States
- Why
- To address vulnerabilities in drug supply, ensure transparency, and mitigate national security risks
- Legislation Proposed
- CLEAR LABELS Act
- Generic Drug Statistics
- 91% of US prescriptions are for generics, 94% use overseas APIs
- Key Countries
- China and India
- FDA Concerns
- Carcinogenic impurities, falsified records, non-sterile conditions
- Consumer Preference
- Prefer US/Canada-made drugs over India/China when origin disclosed
- Expert Recommendations
- QR codes on packaging, public quality data, domestic manufacturing incentives
- Hearing Details
- Senate Special Committee on Aging, record open until next week